Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.38 |
| ▸ | GNRHR | P30968 | 3/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL349262 | 0.90 | CYP3A4 (0.58) | CYP3A4L3MBTL1POLBALDH1A1KMT2A | |
| SCHEMBL350058 | 0.88 | CYP3A4 (0.62) | CYP3A4TP53L3MBTL1POLBALDH1A1 | |
| SCHEMBL348678 | 0.88 | CYP3A4 (0.49) | CYP3A4L3MBTL1ALDH1A1KMT2ALMNA | |
| SCHEMBL347667 | 0.88 | CYP3A4 (0.62) | CYP3A4L3MBTL1ALDH1A1KMT2ALMNA | |
| SCHEMBL350097 | 0.86 | CYP3A4 (0.49) | CYP3A4L3MBTL1ALDH1A1KMT2ALMNA | |
| SCHEMBL350117 | 0.85 | MAPT (0.47) | CYP3A4TP53L3MBTL1POLBALDH1A1 | |
| SCHEMBL348580 | 0.85 | CYP3A4 (0.46) | CYP3A4L3MBTL1POLBALDH1A1KMT2A | |
| SCHEMBL13521848 | 0.85 | TP53 (0.48) | CYP3A4TP53L3MBTL1POLBALDH1A1 | |
| SCHEMBL350212 | 0.84 | CYP3A4 (0.46) | CYP3A4L3MBTL1POLBALDH1A1KMT2A | |
| SCHEMBL348373 | 0.84 | CYP3A4 (0.46) | CYP3A4L3MBTL1POLBALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247602-B2 | Antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120016029-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-01-19 | — | — | US | disclosed |
| US-8071807-B2 | Antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2011-12-06 | — | — | US | disclosed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110144160-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2307362-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | Amira Pharmaceuticals, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20100004331-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| WO-2010003120-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010003127-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016029-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | CYP3A4 1441/4885TP53 4519/4885L3MBTL1 4068/4885 |
| US-20100004331-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | CYP3A4 1441/4885TP53 4519/4885L3MBTL1 4068/4885 |
| US-20110144160-A1 | Antagonists of Prostaglandin D2 Receptors | PTGDR, PTGDR2, PTGER2 | CYP3A4 1441/4885TP53 4519/4885L3MBTL1 4068/4885 |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | PTGDR, PTGDR2, PTGER2 | CYP3A4 1367/4885TP53 4540/4885L3MBTL1 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.